When depression has remained present despite trying treatment, hearing about a different option can bring both hope and questions. This Spravato eligibility guide explains who may be a candidate for this FDA-approved treatment, what a psychiatric evaluation considers, and why safety monitoring is part of every treatment visit.
Spravato is the brand name for esketamine, a nasal-spray medication used alongside an oral antidepressant for certain adults with major depressive disorder. It is not a first-step treatment for every person with depression. Instead, it may be considered when standard approaches have not provided enough relief or when symptoms require a more specialized level of outpatient care.
Who may qualify for Spravato treatment?
The most common reason a provider may discuss Spravato is treatment-resistant depression. In practical terms, this generally means a person has major depressive disorder and has not experienced adequate improvement after trying at least two antidepressant medications at appropriate doses and for an appropriate length of time.
That definition is a starting point, not a checklist a person must solve alone. A qualified psychiatric provider reviews which medications were used, whether they were taken consistently, how long they were tried, whether side effects limited treatment, and whether therapy or other supports have been part of the plan. Depression can be persistent for many reasons, and a careful review helps distinguish a medication that was not a good fit from truly treatment-resistant symptoms.
Spravato may also be considered for adults with major depressive disorder who have acute suicidal thoughts or behaviors, when a provider determines it is clinically appropriate. This indication has its own assessment process and does not replace urgent crisis care when someone cannot stay safe. If you or someone else is in immediate danger or may act on thoughts of self-harm, call 911, go to the nearest emergency department, or call or text 988 for the Suicide & Crisis Lifeline.
Spravato is FDA approved for adults. A provider will determine whether a person’s age, diagnosis, medical history, current medications, and treatment goals make it a reasonable option. It is not approved as a general treatment for sadness, stress, anxiety alone, or every type of mood concern.
What happens during a Spravato eligibility evaluation?
An evaluation should feel like a clinical conversation, not a test. The goal is to understand the full picture of your symptoms and build a plan that fits your needs. Your provider may ask about low mood, loss of interest, sleep, appetite, concentration, energy, hopelessness, and how depression is affecting work, school, relationships, or daily responsibilities.
They will also review your treatment history in detail. Bringing a list of past and current medications, approximate dates, doses if known, side effects, previous psychiatric care, hospitalizations, and therapy experiences can make the discussion more productive. If you do not remember every detail, that is okay. Pharmacy records and prior treatment records may help fill in the gaps.
A thorough evaluation also screens for conditions that can affect diagnosis or treatment planning. Anxiety, trauma and PTSD, ADHD, substance use concerns, insomnia, bipolar disorder, psychosis, and medical conditions can overlap with or complicate depression. This does not automatically rule out Spravato. It means the care team needs to treat the person, not just a single symptom score.
For example, someone with bipolar disorder needs a careful assessment because antidepressant-based treatment strategies can require additional safeguards. Someone experiencing active substance misuse may need coordinated support to address safety and recovery needs. A history of trauma may make psychotherapy an especially valuable part of the treatment plan, even if medication is also appropriate.
Safety factors that may affect eligibility
Spravato can cause temporary sedation, dissociation, dizziness, nausea, and increases in blood pressure. Dissociation may feel like being detached from yourself, your thoughts, time, or your surroundings. These effects are usually monitored and expected to resolve during the observation period, but they are a key reason Spravato is given only in a certified clinical setting.
Certain medical histories may mean Spravato is not appropriate. Your provider will ask about blood vessel conditions, bleeding in the brain, uncontrolled high blood pressure, liver concerns, and other health issues. They will also review all medications and substances you use, including prescribed stimulants, sedatives, sleep medications, opioids, alcohol, and cannabis. Honest answers protect your safety and help the provider make sound recommendations without judgment.
Pregnancy, plans for pregnancy, and breastfeeding should also be discussed before starting treatment. Do not stop prescribed medications on your own while exploring Spravato. Your psychiatric provider can help you weigh benefits, risks, and alternatives based on your circumstances.
Why observation after each dose is required
Spravato is available only through a program called the Spravato REMS program. REMS stands for Risk Evaluation and Mitigation Strategy. This FDA-required program is designed to make sure the medication is administered and monitored safely.
At a REMS-certified treatment center, patients self-administer the nasal spray under the supervision of trained staff and remain at the clinic for observation for at least two hours. Blood pressure is checked, and the team monitors for sedation, dissociation, and other side effects. Patients cannot drive themselves home after treatment or operate machinery until the next day after a restful night of sleep, so transportation must be arranged in advance.
This structure can sound demanding, especially for people balancing work, parenting, or transportation barriers. Yet the observation requirement is not simply an administrative step. It gives patients a protected setting and gives clinicians an opportunity to respond if symptoms or side effects need attention. Weekend availability and a clear scheduling plan can make ongoing treatment more manageable for some families.
What treatment usually looks like
If Spravato is recommended, it is used with an oral antidepressant rather than as a stand-alone medication. The early phase usually involves two treatment visits per week, followed by less frequent visits as the care plan progresses. The exact schedule depends on the FDA-approved treatment framework, your clinical response, side effects, and your provider’s recommendations.
Response varies. Some people notice improvement relatively early, while others need more time to assess whether treatment is helping. Spravato is not a promise of immediate relief, and it does not remove the value of psychotherapy, healthy routines, sleep support, or ongoing medication management. For many people, the strongest plan combines these supports in a coordinated way.
Your provider will regularly track symptoms and functioning rather than relying only on whether you feel better on a particular day. Meaningful progress can include getting out of bed more consistently, returning to responsibilities, feeling more connected to family, sleeping more reliably, or having fewer days dominated by hopelessness.
Insurance and practical planning
Insurance coverage for Spravato often requires prior authorization. Plans commonly ask for documentation of a major depressive disorder diagnosis, past antidepressant trials, and the reason a specialized treatment is medically necessary. Coverage rules differ among commercial plans, Medicare, and Medicaid, so eligibility for treatment and insurance approval are related but separate questions.
Before beginning, ask the office what records may be needed, whether your plan requires authorization, what your expected out-of-pocket costs may be, and how treatment visits will be scheduled. It is also helpful to plan transportation for each appointment and arrange support at home if you are likely to feel tired after returning from the clinic.
At Smart Minds Psychiatry, a Spravato REMS-certified facility in Grand Rapids, treatment planning can be coordinated with psychiatric evaluations, medication management, psychotherapy, and other mental health services. That continuity matters because treatment-resistant depression rarely affects only one part of a person’s life.
A conversation worth having
Feeling discouraged after unsuccessful depression treatment is understandable, but it does not mean you have run out of options. A thoughtful Spravato evaluation can clarify whether this treatment fits your diagnosis, health history, safety needs, and daily life. The next helpful step is simply to speak with a qualified psychiatric provider who will listen carefully, explain your options plainly, and help you move forward at a pace that feels supported.